Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

U.S. + International

AEterna Zentaris Inc (NASDAQ:AEZS)

Add to Watch List
Set Alert
3.38
BATS BZX Real-Time Price
As of 1:28pm ET
 -0.07 / -2.03%
Today’s Change
2.60
Today|||52-Week Range
15.70
-24.55%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$34.3M

Company Description

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company that is engaged in developing and commercializing novel treatments in oncology, endocrinology and women's health. The company's pipeline encompasses compounds at all stages of development, from drug discovery through to marketed products. It focuses on the development of Perifosine, Cetrotide, Ozarelix, AEZS-108 and AEZS-130. AEterna Zentaris was founded on September 12, 1990 and is headquartered in Montreal, Canada.

Contact Information

Æterna Zentaris, Inc.
1 Place Marie
Montréal Quã©bec H3B 1R1
P:(514) 847-4747
Investor Relations:
(843) 900-3211

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

David A. DoddPresident, Chief Executive Officer & Director
Geneviève LemaireChief Accounting Officer & Vice President-Finance
Richard SachseSenior VP, Chief Scientific & Medical Officer
Philip A. TheodoreSecretary, Chief Administrative Officer & SVP
Eckhard G. GuentherVice President-Business Development